Cranbury, NJ – February 12, 2015 — Oncobiologics, Inc.,a biotherapeutics company focused on developing and commercializing biosimilars,announced today that ONS-3010, its adalimumab (Humira®) biosimilar candidate met the primary endpoints in its first clinical study.

Cranbury, NJ  -- October 7, 2014 – Oncobiologics, Inc., a biotherapeutics company focused on developing and commercializing complex biosimilars, announced the appointment of Aldeyra Therapeutics CEO Todd C. Brady, M.D., Ph.D, to its Board of Directors.

July 16, 2014:  Cranbury, NJ  Strides Arcolab and Oncobiologics, Inc., today announced that Strides has made a series of strategic investments in Oncobiologics, Inc, a privately held New Jersey biopharmaceutical firm developing a pipeline of biosimilars and next generation biotherapeutics.

Cranbury, NJ – June 26, 2014 — Oncobiologics, Inc. and Laboratorios Liomont S.A. de C.V. announced today a strategic partnership for the development, manufacture and commercialization of biosimilar monoclonal antibody products for the Mexican market.  The scope of the agreement includes exclusive

Cranbury, NJ – June 12, 2014 — Oncobiologics, Inc. announced today that it has received approval to initiate a Phase I clinical trial in Europe for its first biosimilar molecule, ONS-3010, a highly biosimilar version of the marketed drug, Humira®. After reviewing Oncobiologics’ Clinical Trial

Mumbai, India and New Jersey, USA – June 2, 2014 — Ipca Laboratories Ltd., India (Ipca) and Oncobiologics, Inc., USA (Oncobiologics) announced today the creation of a two-part alliance for the development, manufacture and commercialization of biosimilar monoclonal antibody products.  Under the

Oncobiologics Founder and CEO Pankaj Mohan, Ph.D. was named a finalist in the EY Entrepreneur Of The Year 2014 for New Jersey program. This award recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation, financial performance and personal commitment